News
| 3 min read
Structural insights reveal how DCAF2 can be harnessed to target previously untouchable proteins for degradation.
| 2 min read
Nearly 25 percent of non-antibiotic drugs tested in the study enabled the proliferation of enteropathogens.
| 6 min read
New software and hardware tools that collect data while a person types can detect fine motor impairment — a possible sign of neurodegeneration.
| 9 min read
Scientists are advancing CAR T cell therapy to improve outcomes for children with acute lymphoblastic leukemia.
| 4 min read
An FDA rejection, Takeda restructuring, Trump initiatives and more lead the news this week.
| 4 min read
AI has moved beyond buzzword status to become a core technology in pharmaceutical R&D.
| 7 min read
With blockbuster status secured, GLP-1 therapies face new questions about efficacy, delivery, and their role in treating multiple chronic diseases.
| 3 min read
Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.
| 5 min read
Advances in allosteric inhibitors may offer a new standard of care that balances potent disease control with better tolerability and convenience.
| 3 min read
A novel cannabis-based therapy shows promise as a safe, effective non-opioid alternative for chronic low back pain.
| 3 min read
Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.
| 3 min read
Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.
